icon-folder.gif   Conference Reports for NATAP  
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
Predictors of Mortality among United States Veterans with Hepatitis C Virus Infection: 'almost double mortality rate in HCV+ vs HCV- HCV treatment reduced mortality by 50%'
  Reported by Jules Levin
EASL 2013 April 25-28 Amsterdam
Sebhat Erqou MD PhD1,2, Arpan Mohanty MD1, Adeel A. Butt MD MS 2, 3,4 1. University of Pittsburgh Medical Center (UPMC); 2. Veterans Administration (VA) Pittsburgh Healthcare System; 3. University of Pittsburgh School of Medicine;
4. Sheikh Khalifa Medical City, Abu Dhabi, UAE.
excerpt from EASL NATAP Report by Jurgen Rockstroh:
"Overall they were able to compare an impressive number of 195,585 HCV Patients with 202,739 non-HCV infected veterans. The all-cause mortality rate among Veterans with HCV infection was much higher with 43.9 (43.4-44.3) per 1000 person-years (PY) than in Veterans without HCV infection (all-cause mortality was 24.0 (23.7-24.4) per 1000 PY). The table 1 shows the relevant predictors found to impact mortality. Among Veterans with HCV infection, decompensated liver disease, anemia, cancer, chronic kidney disease and COPD were the strongest predictors of higher risk of mortality, while HCV treatment was associated with over 50% reduction in mortality in this group. These findings once again underline the importance of HCV therapy to significantly lower risk of mortality in HCV infected individuals."
EASL: Summary from EASL 2013 for Hepatitis C - New HCV DAAs on their way soon: what do the phase III studies tell us? - written by - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (05/16/13)